**S4 Table.** Baseline demographic and clinical characteristics of the patients Covid-19 included in the prospective observational study, according to initial diarrhea.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics**  |  | **COVID-19 initial symptom** |  |  |
|  | **Diarrhea** |  |  | **No Diarrhea**  | **P value** |
| Number n (%) | 29 (100%) |  |  | 102 (100%) |  |
| Median age (IQR) year | 65.1 (56.2-79.7) |  |  | 71.7 (58.8-82.8) | 0.34 |
| Age category  |  |  |  |  | 0.76 |
|  <50 year | 4 (13.8) |  |  | 13 (12.8) |  |
|  50 to <70 year | 11 (33.9) |  |  | 32 (31.4) |  |
|  >=70 year | 14 (48.3) |  |  | 57 (55.9) |  |
| Male sex  | 18 (61.5) |  |  | 57(55.9) | 0.55 |
| Time clinic-inclusion (days) | 9 (6-14) |  |  | 9 (5-14) | 0.74 |
| Geographic origin  |  |  |  |  | 0.78 |
|  Caucasian | 62 (56.9) |  |  | 63 (71.7) |  |
|  Subsaharan | 4 (17.8) |  |  | 13 (12.8) |  |
|  North African, Middle East | 6 (20.7) |  |  | 15 (14.7) |  |
|  Asian | 4 (10.1) |  |  | 11 (10.8) |  |
| Oxygen-support category  |  |  |  |  | 0.19 |
|  Invasive oxygen support | 0 |  |  | 0 |  |
|  Noninvasive oxygen support | 18 (62.1) |  |  | 76 (74.5) |  |
|  None | 11 (37.9) |  |  | 26 (25.5) |  |
| Coexisting conditions  |  |  |  |  |  |
|  Hypertension | 13 (44.8)  |  |  | 58 (56.9) | 0.25 |
|  Diabetes | 5 (17.2) |  |  | 27 (26.7) | 0.40 |
|  Hyperlipidemia | 6 (20.7) |  |  | 30 (29.4) | 0.35 |
|  Liver disease | 3 (10.3) |  |  | 11 (10.7) | 1.00 |
|  Pulmonary disease | 6 (20.7) |  |  | 8 (7.9) | 0.08 |
|  Severe disease associated | 15 (51.7) |  |  | 58 (57.4) | 0.59 |
| Tobacco (ongoing or stopped) | 12 (41.4)  |  |  | 29 (28.4) | 0.19 |
| Alcohol consumption | 4 (13.8) |  |  | 15 (14.7) | 0.90 |
| Initial presentation  |  |  |  |  |  |
| Anosmia | 4 (14.3) |  |  | 11 (11.6) | 0.74 |
| Ageusia | 3 (10.7) |  |  | 16 (16.8) | 0.56 |
| Headache | 5 (17.9) |  |  | 9 (9.5) | 0.31 |
| Rhinorrhea | 0 (0) |  |  | 6 (6.3) | 0.34 |
| Dyspnea | 19 (67.9) |  |  | 48 (50) | 0.10 |
| Wheezing | 0 (0) |  |  | 3 (3.1) | 1.00 |
| Cough without spitting | 9 (32.1) |  |  | 44 (45.8) | 0.20 |
| Cough with spitting | 5 (17.9) |  |  | 15 (15.6) | 0.77 |
| Fatigue | 18 (64.3 |  |  | 44 (46.3) | 0.32 |
| Median laboratory (IQR) |  |  |  |  |  |
| Apolipoprotein-A1 g/L | 0.87 (0.68-0.98) |   |   | 0.83 (0.70-1.05) | 0.89 |
| Apolipoprotein <= 1.25g/L (%) | 1 (3.5) |   |   | 11 (10.8) | 0.30 |
| Haptoglobin g/L | 2.98 (2.01-3.91) |   |   | 3.17 (2.23-4.19) | 0.31 |
| Alpha-2 macroglobulin g/L | 1.47 (1.12-1.88) |   |   | 1.50 (1.24-2.07) | 0.38 |
| GGT IU /L | 49 (32-105) |   |   | 50 (30-119) | 0.92 |
| ALT IU /L | 34 (28-46) |   |   | 29 (19-52) | 0.41 |
| Total bilirubin micromol/L | 8 (6-9) |   |   | 8 (7-9) | 0.92 |
| Platelets 106 per ml (6 missing) | 220 (132-285) |   |   | 221 (169-290) | 0.53 |
| Creatinine µmol /L (6 missing) | 78 (63-122) |   |   | 79 (63-103) | 0.76 |
| Fasting Glucose (24 missing) | 6 (5.2-7.95) |   |   | 6.1 (5.4-7.93) | 0.79 |

|  |  |  |  |
| --- | --- | --- | --- |
| Albumin g/L (13 missing) | 30 (27-32) | 31 (27-34) | 0.15 |
| Procalcitonin (12 missing) | 0.135 (0.078-0.230) | 0.130 (0.080-0.280) | 0.98 |
| C-reactive protein (8 missing) | 56 (29-78) | 60 (17-106) | 0.61 |
| InterLeukin-6 (33 missing) | 31.4 (9.55-45.58) | 30 (14.83-61.78) | 0.56 |
| CPK IU /L (13 missing) | 69 (42-144) | 109 (46-241) | 0.21 |
| AST IU /L (6 missing) | 49 (31-62) | 41 (29-57)  | 0.27 |
| LDH (11 missing) | 343 (262-429) | 347 (282-420) | 0.98 |
| D-dimer (19 missing) | 1245 (645-1925) | 1115 (548-2230) | 0.69 |
| Troponin (9 missing) | 12.95 (8.06-31.08) |  17.45 (10.1-39.33) | 0.19 |
| Prothrombin time % (11 missing) | 92 (89-97) | 88 (78-100) | 0.27 |
| White cells |   |   |   |
| Neutrophil (9 missing) | 3235 (2510-4490) | 4850 (3118-6708) | 0.003 |
| Eosinophil (7 missing) | 0 (0-48) | 0.1 (0-30) | 0.98 |
| Lymphocyte (9 missing) | 975 (655-1358) | 975 (685-1265) | 0.97 |
| Hemoglobin g/L (7 missing) | 12.2 (11.2-14.5) | 12.3 (11.1-13.5) | 0.67 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment at risk of DILI |  |  |  |  |  |
|  Paracetamol oral (2-4 g/day) | 13 (44.8) |  |  | 33 (32.7) | 0.21 |
|  Antibiotics |  |  |  |  | 0.92 |
|  None | 6 (20.7) |  |  | 20 (19.6) |  |
|  Without clavulinate | 41 (37.6) |  |  | 9 (47.4) |  |
|  With clavulinate | 16 (55.2) |  |  | 38 (37.3) |  |
| Steroids | 2 (6.9) |  |  | 11 (9.9) | 0.54 |
| Hydroxy chloroquine | 15 (51.7) |  |  | 38 (37.3) | 0.16 |
| No Intensive care no death | 25 (86.2) |  |  | 74 (73.3) | 0.15 |
| Transfer intensive care unit | 2 (6.9) |  |  | 18 (16.8) | 0.24 |
| Death | 3 (10.3) |  |  | 13 (12.9) | 0.73 |